Table 1.
Observed and predicted treatment effect on overall survival, based on the observed treatment effect on progression-free survival*
| Trial label | Trial | Observed HRPFS (95% CI) | Observed HROS (95% CI) | Predicted HROS (95% CI) |
|---|---|---|---|---|
| A | Jeung et al. (36) | 0.63 (0.38 to 1.05) | 0.56 (0.35 to 0.88) | 0.73 (0.46 to 1.04) |
| B | AIO (33) | 0.67 (0.43 to 1.04) | 0.82 (0.47,1.45) | 0.76 (0.53 to 1.07) |
| C | ToGA (10) | 0.71 (0.59 to 0.85) | 0.74 (0.60 to 0.91) | 0.80 (0.58 to 1.09) |
| D | AVAGAST (9) | 0.80 (0.68 to 0.93) | 0.87 (0.73 to 1.03) | 0.88 (0.76 to 1.14) |
| E | Kang et al. (35) | 0.80 (0.63 to 1.03) | 0.85 (0.64 to 1.13) | 0.88 (0.76 to 1.14) |
| F | Park et al. (38) | 0.86 (0.54 to 1.37) | 0.96 (0.60 to 1.52) | 0.93 (0.71 to 1.18) |
| G | REAL (a)† (34) | 0.92 (0.80 to 1.04) | 0.92 (0.80 to 1.10) | 0.98 (0.77 to 1.22) |
| H | REAL (b) (34) | 0.92 (0.81 to 1.05) | 0.86 (0.80 to 0.99) | 0.98 (0.77 to 1.22) |
| I | Ross et al. (39) | 0.95 (0.80 to 1.08) | 0.91 (0.76 to 1.04) | 1.00 (0.79 to 1.29) |
| J | FLAGS (32) | 0.99 (0.86 to 1.14) | 0.92 (0.80 to 1.05) | 1.03 (0.81 to 1.31) |
| K | Rao et al. (11) | 1.13 (0.63 to 2.01) | 1.02 (0.61 to 1.70) | 1.14 (0.89 to 1.46) |
| L | Moehler et al. (37) | 1.14 (0.59 to 2.21) | 0.77 (0.51 to 1.17) | 1.15 (0.90 to 1.48) |
* HR = hazard ratio; PFS = progression-free survival; CI = confidence interval; OS = overall survival.
† This trial was designed as a factorial 2×2 plan to test two comparisons: a platinum comparison (a) and a fluoropyrimidine comparison (b).